A thank you to all the Co authors in the study and of course the patients. @dbhurani @Reema_Shayra
#Thalassemia #QoL #HSCT
English
Rohan Halder
199 posts
Rohan Halder
@Rohanhematdoc
Clinical hematologist; Transplant physician
New Delhi, India 가입일 Ocak 2020
348 팔로잉203 팔로워
India faces a major healthcare burden of Transfusion Dependent Thalassemia.
Transplant is a curative treatment available for patients who have a Matched sibling donor.
An important question that arises is does transplant make a difference in long term quality of life
English
Transplant had a profound, long-term improvement in the multi-dimensional quality of life for children suffering from beta -thalassemia major.
Please find the link to the study. url6649.tandfonline.com/ls/click?upn=u…
English
Graft versus host disease had a negative impact on quality of life.
English
Used The PedsQL 4.0 Generic Core Scales to assess QOL. Significant Overall Improvement: The transplant (Tx) group scored significantly higher across all domains of health-related quality of life compared to the non-transplant (NTx) group (p < 0.05). This includes improvements
English
@HiraSMian @rajshekharucms @Rfonsi1 @RahulBanerjeeMD @DrRakeshPopat @bdermanmd @HadidiSamer I had the opportunity to use Elrana as a part of CUP in RRMM. The peripheral neuropathy/GBS was so debilitating that the patient said he had had enough of the drug, wanted it stopped for him.
English
are folks seeing this in clinic practise with bispecifics? @rajshekharucms @Rfonsi1 @RahulBanerjeeMD @DrRakeshPopat @bdermanmd @HadidiSamer, any treatment strategies or risk factor for neuropathy? I have a small number of patients we are using high dose IVIG for neuropathy.
English
HR SMM, "peripheral neuropathy (20%), mostly grade 1–2 and 1 case of GBS". This seems really high for a patient population that has not received any prior treatment....Grade 1/2 neuropathy can have unporportional impairement on QoL.
Daniel Auclair@AuclairDan
2/ @ASCO #ASCO26 #myeloma #mmsm - ERASMM Elra in HR SMM asco.org/abstracts-pres… - Optec/Optal asco.org/abstracts-pres… - BelaDRd in TI NDMM asco.org/abstracts-pres… - IEC-EC in CARTITUDE studies asco.org/abstracts-pres…
English
Rohan Halder 리트윗함
3/ @ASCO #ASCO26 #myeloma #mmsm
- Impact of 5-Year Sustained MRD negativity in FORTE
asco.org/abstracts-pres…
- cfDNA WGS vs Mass Spec
asco.org/abstracts-pres…
And one bonus thought-provoking on differences in access to CARTs
asco.org/abstracts-pres…
English
@Papa_Heme I hope you are not being sarcastic.
An expert once told me what are you gonna do with it if you had access?
English
Honestly I can’t wait until ctDNA becomes prime time for monitoring response to cancer treatment. I’ll gladly never order a scan again.
Steven Bonebrake@StevenBonebrake
@Papa_Heme If you stop ordering scans you won't have any incidentalomas to follow-up on.
English
@BloodCancerJnl Would be keen to understand what they do in a CHIP clinic? And what profile of patients are seen in a CHIP clinic
English
CHIP clinics: a practical overview of structure and function | Blood Cancer Journal nature.com/articles/s4140…
English
How do you manage Progressive Disease in Myeloma post Bispecifics ( Teclistamab )? Is there any approach?
Can we induce sensitivity of Bispecifics- Plasma exchange+/-DTPACE/IMid like Therapy?
@RahulBanerjeeMD @VincentRK @myelomaMD @Rfonsi1 @rajshekharucms @kansagraM
English
Rohan Halder 리트윗함
Hematologists treat acute leukemias at most centers across the country . Excluding hematologists from clinical trials of “HEMATOLOGICAL MALIGNANCIES “ makes absolutely no sense and is an irony in itself . Really unfortunate that instead of widening access to patients , policy decisions ignore ground realities and come up with such absurd ideas @jayastuMD @royjpalatty @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TribikramHemat @TikareNakul @Rohanhematdoc @shanuaswam @RahulDoc2 @dranupjdevasia
Prantar Chakrabarti 3.0@prantar
Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat
English
@nikhil91sjmc I think it is one of most obnoxious orders I have seen. Makes me question the credibility of the organisation.
English
Rohan Halder 리트윗함
Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat
English
@GomezDLeonMD Too bad. There is a Phase 2 Rituxumab+ Benda study. You could do that.
English
How would you treat a person with a hairy cell leukemia without these drugs:
- Cladribine
- Pentostatin
- Interferon
- Vemurafenib
None available in 🇲🇽 as big pharma is not interested in selling them here (despite 3/4 having regulatory authorization!).
#Leusm #Lymsm #Askingforafriend
English
@HadidiSamer @OncJournal @utswcancer @ldandersonjr @AimazAfrough @khancology Thank you. The article gave me a great insight about how to use them. Do you step down dosing to every 4 weeks irrespective of disease cytogenetics/high risk features if response is >VGPR?
English
Check our recent publication : BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions @OncJournal @utswcancer @ldandersonjr @AimazAfrough @khancology #mmsm academic.oup.com/oncolo/article…
English